T-DXd is an antibody-drug conjugate consisting of a humanized monoclonal anti-HER2 antibody joined to a
T-DXd continues to demonstrate a generally tolerable safety profile with few treatment discontinuations due to
In this analysis, the risk of adjudicated drug-related ILD appears lower after approximately 12
Median follow-up was 20.5 months (range, 0.7-31.4 months), representing an additional 9.4 months from the
DESTINY-Breast01 (NCT03248492) is a phase 2, open-label, multicenter, 2-part study evaluating T-DXd in adult
Prior T-DM1
Demographic and baseline clinical characteristics are shown in Table 1
A total of 184 patients who had received ≥2 anti
3 new cases of T-DXd–related ILD as determined by an independent adjudication committee were reported (Table
Excluded patients with
Based on these results, T-DXd was approved for the treatment of adult patients with HER2-positive,
The estimated percent of patients alive at 12 and 18 months was 85% (95% CI, 79%-90%) and 74% (95% CI,
METHODS
RESULTS
METHODS
RESULTS
CONCLUSIONS
REFERENCES
ACKNOWLEDGMENTS
DISCLOSURES